Cite
HARVARD Citation
Newland, A. et al. (n.d.). Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. American journal of hematology. 95 (2), pp. 178-187. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Newland, A. et al. (n.d.). Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. American journal of hematology. 95 (2), pp. 178-187. [Online].